Mineralys Therapeutics MLYS Income Statement (2022-2026)

NASDAQ MLYS
$28.21 -0.06 (-0.21%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Mineralys Therapeutics Quarterly Income Statement

Periods 18 quarters
Latest Jun 2026

Mineralys Therapeutics reported net income of -$241.07M for the quarter ended Jun 2026. This income statement covers 18 quarters of results from Mar 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.) 5.61M5.61M5.18M5.17M24.76M40.86M41.11M41.13M49.63M49.71M49.76M49.82M53.16M65.73M78.97M67.66M82.45M88.35M
Operating items
Research & DevelopmentR&D 6.78M5.59M6.06M7.82M12.29M11.88M22.50M23.68M30.75M39.27M53.98M44.57M37.88M38.28M31.45M24.40M24.36M221.38M
Selling, General & AdministrativeSG&A 0.79M0.88M1.36M2.19M2.65M3.85M3.77M4.03M4.61M5.89M6.12M7.20M6.57M8.47M9.68M13.88M20.98M24.66M
Operating ExpensesOpex 7.57M6.48M7.42M10.01M14.94M15.73M26.27M27.71M35.36M45.17M60.11M51.77M44.45M46.75M41.13M38.28M45.34M246.04M
Operating IncomeOp. Inc -7.57M-6.48M-7.42M-10.01M-14.94M-15.73M-26.27M-27.71M-35.36M-45.17M-60.11M-51.77M-44.45M-46.75M-41.13M-38.28M-45.34M-246.04M
EBIT -7.57M-6.48M-7.42M-10.01M-14.94M-15.73M-26.27M-27.71M-35.36M-45.17M-60.11M-51.77M-44.45M-46.75M-41.13M-38.28M-45.34M-246.04M
Non-operating items
Interest & Investment IncomeInt & Inv Inc 0.74M0.94M2.33M3.59M3.51M3.32M3.85M4.15M3.77M2.81M2.24M3.47M4.20M6.04M6.00M4.96M
Other Non Operating IncomeOther Non Op Inc. 0.00M0.00M0.00M0.00M0.00M0.00M-0.01M0.01M-0.00M-0.00M0.00M0.00M0.01M0.01M
Non Operating IncomeNon Op. Inc. 0.74M0.94M2.33M3.59M3.51M3.32M3.85M4.15M3.76M2.82M2.24M3.47M4.20M6.05M6.00M4.97M
Net income details
EBT -7.57M-6.48M-6.68M-9.07M-12.61M-12.14M-22.76M-24.39M-31.51M-41.02M-56.33M-48.96M-42.21M-43.27M-36.94M-32.23M-39.34M-241.08M
Profit After TaxPAT -7.57M-6.48M-6.68M-9.07M-12.61M-12.14M-22.76M-24.39M-31.51M-41.01M-56.34M-48.95M-42.21M-43.27M-36.93M-32.28M-39.34M-241.07M
Income from Continuing OperationsIncome (Continuing) -7.57M-6.48M-6.68M-9.07M-12.61M-12.14M-22.76M-24.39M-31.51M-41.02M-56.33M-48.96M-42.21M-43.27M-36.94M-32.23M-39.34M-241.08M
Consolidated Net IncomeConsol Net Inc. -7.57M-6.48M-6.68M-9.07M-12.61M-12.14M-22.76M-24.39M-31.51M-41.02M-56.33M-48.96M-42.21M-43.27M-36.94M-32.23M-39.34M-241.08M
Income towards Parent CompanyParent Net Inc -7.57M-6.48M-6.68M-9.07M-12.61M-12.14M-22.76M-24.39M-31.51M-41.02M-56.33M-48.96M-42.21M-43.27M-36.94M-32.23M-39.34M-241.08M
Net Income towards Common StockholdersNet Income -7.57M-6.48M-6.68M-9.07M-12.61M-12.14M-22.76M-24.39M-31.51M-41.02M-56.33M-48.96M-42.21M-43.27M-36.94M-32.23M-39.34M-241.08M
Additional items
EPS (Basic) -1.48-1.26-1.29-1.76-0.51-0.31-0.57-0.67-0.70-0.83-1.13-1.01-0.79-0.66-0.52-0.48-0.47-2.85
EPS (Diluted) -1.48-1.26-1.29-1.76-0.51-0.31-0.57-0.67-0.70-0.83-1.13-1.01-0.79-0.66-0.52-0.48-0.47-2.85
Shares Outstanding 5.12M5.15M5.18M5.17M24.76M39.75M39.93M36.19M44.90M49.36M49.82M48.54M53.16M65.45M70.59M67.66M82.83M84.73M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 5.12M5.15M5.18M5.17M24.76M39.75M39.93M36.19M44.90M49.36M49.82M48.54M53.16M65.45M70.59M67.66M82.83M84.73M
EBITDA -7.57M-6.48M-7.42M-10.01M-14.94M-15.73M-26.27M-27.71M-35.36M-45.17M-60.11M-51.77M-44.45M-46.75M-41.13M-38.28M-45.34M-246.04M